News und Analysen
Evolva's Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items:
Evolva's Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items:
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
DGAP-News: Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
DGAP-News: Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
DGAP-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu, genehmigt die Dividende von CHF 3.85 pro Aktie und wählt zwei neue Verwaltungsräte
DGAP-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu, genehmigt die Dividende von CHF 3.85 pro Aktie und wählt zwei neue Verwaltungsräte
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Kuros Biosciences reports results for the full year 2021
Kuros Biosciences reports results for the full year 2021
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Evolva grew product-related revenue by 40% in 2021
Evolva grew product-related revenue by 40% in 2021
DGAP-News: BB Biotech AG veröffentlicht Geschäftsbericht 2021
DGAP-News: BB Biotech AG veröffentlicht Geschäftsbericht 2021
DGAP-News: BB Biotech AG publishes its 2021 annual report
DGAP-News: BB Biotech AG publishes its 2021 annual report
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
Evolva appoints Christian Wichert as new CEO to boost growth strategy and enter its next phase of development and commercialization
Evolva appoints Christian Wichert as new CEO to boost growth strategy and enter its next phase of development and commercialization
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
EQS-Adhoc: Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
EQS-Adhoc: Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
EQS-Adhoc: Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
EQS-Adhoc: Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
EQS-Adhoc: Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
EQS-Adhoc: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
EQS-Adhoc: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
DGAP-Adhoc: BB Biotech AG mit Verlust im Geschäftsjahr 2021
DGAP-Adhoc: BB Biotech AG mit Verlust im Geschäftsjahr 2021